Editas Medicine Inc (NASDAQ: EDIT) started the day on Thursday, with a price increase of 2.36% at $1.30, before settling in for the price of $1.27 at the close. Taking a more long-term approach, EDIT posted a 52-week range of $1.12-$7.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 96.99% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -1.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 49.07%. This publicly-traded company’s shares outstanding now amounts to $82.73 million, simultaneously with a float of $82.23 million. The organization now has a market capitalization sitting at $107.87 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5083, while the 200-day Moving Average is $2.9970.
Editas Medicine Inc (EDIT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Editas Medicine Inc’s current insider ownership accounts for 0.91%, in contrast to 62.52% institutional ownership. According to the most recent insider trade that took place on Mar 04 ’25, this organization’s EVP, CHIEF FINANCIAL OFFICER sold 4,109 shares at the rate of 1.71, making the entire transaction reach 7,030 in total value, affecting insider ownership by 112,720. Preceding that transaction, on Mar 04 ’25, Company’s CEO sold 16,632 for 1.71, making the whole transaction’s value amount to 28,452. This particular insider is now the holder of 295,474 in total.
Editas Medicine Inc (EDIT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
Editas Medicine Inc’s EPS increase for this current 12-month fiscal period is 49.07% and is forecasted to reach -1.05 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 23.95% through the next 5 years, which can be compared against the -1.48% growth it accomplished over the previous five years trading on the market.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Let’s observe the current performance indicators for Editas Medicine Inc (EDIT). It’s Quick Ratio in the last reported quarter now stands at 3.75. The Stock has managed to achieve an average true range (ATR) of 0.18. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.34.
In the same vein, EDIT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.88, a figure that is expected to reach -0.56 in the next quarter, and analysts are predicting that it will be -1.05 at the market close of one year from today.
Technical Analysis of Editas Medicine Inc (EDIT)
If we take a close look at the recent performances of Editas Medicine Inc (NASDAQ: EDIT), its last 5-days Average volume was 1.81 million that shows plunge from its year to date volume of 3.94 million. During the previous 9 days, stock’s Stochastic %D was recorded 18.29% While, its Average True Range was 0.1485.
Raw Stochastic average of Editas Medicine Inc (EDIT) in the period of the previous 100 days is set at 7.89%, which indicates a major fall in contrast to 13.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 86.18% that was lower than 156.53% volatility it exhibited in the past 100-days period.
